Literature DB >> 15064691

Predictors for severe cardiac complications after hematopoietic stem cell transplantation.

M Sakata-Yanagimoto1, Y Kanda, M Nakagawa, Y Asano-Mori, K Kandabashi, K Izutsu, Y Imai, A Hangaishi, M Kurokawa, S Tsujino, S Ogawa, S Chiba, T Motokura, H Hirai.   

Abstract

The value of pre-transplant factors for predicting the development of cardiac complications after transplantation has been inconsistent among studies. We analyzed the impact of pre-transplant factors on the incidence of severe cardiac complications in 164 hematopoietic stem cell transplant recipients. We identified eight patients (4.8%) who experienced grade III or IV cardiac complications according to the Bearman criteria. Seven died of cardiac causes a median of 3 days after the onset of cardiac complications. On univariate analysis, both the cumulative dose of anthracyclines and the use of anthracyclines within 60 days before transplantation affected the incidence of severe cardiac complications (P=0.0091 and 0.011). The dissociation of heart rate and body temperature, which reflects "relative tachycardia", was also associated with a higher incidence of cardiac complications (P=0.024). None of the variables obtained by electrocardiography or echocardiography were useful for predicting cardiac complications after transplantation, although the statistical power might not be sufficient to detect the usefulness of ejection fraction. On a multivariate analysis, the cumulative dose of anthracyclines was the only independent significant risk factor for severe cardiac complications. We conclude that the cumulative dose of anthracyclines is the most potent predictor of cardiac complications and the administration of anthracyclines should be avoided within two months before transplantation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064691     DOI: 10.1038/sj.bmt.1704487

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

1.  Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.

Authors:  Patricia A Ford; Shakira J Grant; Rosemarie Mick; Gina Keck
Journal:  J Clin Oncol       Date:  2015-04-13       Impact factor: 44.544

2.  Late congestive heart failure after hematopoietic cell transplantation.

Authors:  Saro H Armenian; Can-Lan Sun; Liton Francisco; Julia Steinberger; Seira Kurian; F Lennie Wong; Jon Sharp; Richard Sposto; Stephen J Forman; Smita Bhatia
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  Cardiac output response to exercise in patients before allogenic hematopoietic stem cell transplantation.

Authors:  Shinya Yoshida; Fujiko Someya; Tetsutaro Yahata
Journal:  Int J Clin Oncol       Date:  2018-07-05       Impact factor: 3.402

4.  Assessment of the ovarian reserve with anti-Müllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding.

Authors:  Hirofumi Nakano; Masahiro Ashizawa; Yu Akahoshi; Tomotaka Ugai; Hidenori Wada; Ryoko Yamasaki; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Miki Sato; Kiriko Terasako-Saito; Shun-Ichi Kimura; Misato Kikuchi; Hideki Nakasone; Shinichi Kako; Junya Kanda; Rie Yamazaki; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2016-04-15       Impact factor: 2.490

5.  Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done?

Authors:  Peter Hurley; Suma Konety; Qing Cao; Daniel Weisdorf; Anne Blaes
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-16       Impact factor: 5.742

6.  Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.

Authors:  Smita Bhatia; Leslie L Robison; Liton Francisco; Andrea Carter; Yan Liu; Marcia Grant; K Scott Baker; Henry Fung; James G Gurney; Philip B McGlave; Auayporn Nademanee; Norma K C Ramsay; Anthony Stein; Daniel J Weisdorf; Stephen J Forman
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

Review 7.  Long-term consequences of hematopoietic stem cell transplantation: current state of the science.

Authors:  K Scott Baker; Saro Armenian; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-24       Impact factor: 5.742

8.  Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction.

Authors:  Muzaffar H Qazilbash; Ali Imran Amjad; Suhail Qureshi; Sofia R Qureshi; Rima M Saliba; Ziad U Khan; Chitra Hosing; Sergio A Giralt; Marcos J De Lima; Uday R Popat; Syed W Yusuf; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2009-08-03       Impact factor: 5.742

Review 9.  Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation.

Authors:  Seth J Rotz; Thomas D Ryan; Salim S Hayek
Journal:  J Thromb Thrombolysis       Date:  2020-11-24       Impact factor: 2.300

10.  Association of persistent tachycardia with early myocardial dysfunction in children undergoing allogeneic hematopoietic cell transplantation.

Authors:  Jason F Goldberg; Emily J Peters; Elizabeth A Tolley; Mazal N Hagler; Vijaya M Joshi; Shelby E Wallace; Simonne S Nouer; Gary S Beasley; Hugo R Martinez; Kaitlin A Ryan; Mohammed A Absi; Jenny R Strelsin; Jeffrey A Towbin; Brandon M Triplett
Journal:  Bone Marrow Transplant       Date:  2021-05-20       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.